Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

5 High-Yield Stocks to Shield Your Portfolio From the Storm

With the S&P 500 breaking below its 200-day SMA, high-yield dividend stocks are increasingly worth considering as a source of income and portfolio protection.

MarketBeat

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.

Euronews

Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their options.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

Barchart

The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients

More than 5,000 shelved drug candidates were discontinued for business reasons, not safety ones. A new push aims to match them with the highest need.

Fortune

The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start. Pfizer (PFE) has been a strong performer in 2026 and is up 9.64% so far this year.

Barchart

Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

Euronews

Read news from The Economist, FT, and more,
with one subscription

RFK Jr’s pick to review Covid vaccines authored misleading research, experts say

HHS calls MIT professor ‘more than qualified’ for advisory panel and calls ‘attacks’ on him ‘politically motivated’

The Guardian - US

The Dividend Safe Harbor: 2 Stocks to Watch

Rising geopolitical tensions, surging oil prices, and increasing volatility are pressuring U.S. equities and driving a shift toward defensive positioning.

MarketBeat

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

Barchart

Health Care Stocks Have Sagged. Can You Bet on a Recovery?

The flagging health care sector has perked up a bit lately. Is it time to invest?

Kiplinger

COVID-19 Vaccine Updates 2026: Booster Shots, Effectiveness, and Expert Guidance

COVID vaccines and booster shots 2025–2026 offer 80–95% protection against JN.1 and KP.2 variants, reducing severe illness and hospitalization.

Medical Daily

UK law firms consider action on behalf of women who developed brain tumours after using contraceptive

Studies show Depo-Provera users have much higher relative risk of developing meningiomas, although overall risk remains low

The Guardian - UK

Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential

Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit potential. Volatility returned to markets yesterday, triggering a tech rout. Among the…

MarketBeat

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

The Independent UK

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

Barchart

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

How Pfizer’s CEO wielded moral clarity to help his team do the impossible

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Fortune

Pfizer CEO Albert Bourla's best leadership advice: Being optimistic is better than being right

Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the key is being someone your peers want to follow.

Fortune

'We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The winners always stand up again."

Fortune

Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.

Saving Advice

7 Prescription Price Increases Linked to Supplier Changes

We often assume drug prices rise solely due to corporate greed or inflation. In 2026, a different force is driving costs up. Structural changes in...

Fortune

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

Also: All the news and watercooler chat from Fortune.

Barchart

What Are Wall Street Analysts' Target Price for Pfizer Stock?

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.